Tuesday, May 1, 2018
7:30 am Conference Registration and Continental Breakfast
8:30 Welcome Keynote and State of the Neurotechnology Industry
The Neurotechnology Industry Organization and guest speakers provide an annual review of trends and developments in neuropharmaceuticals, neurodevices, and neurodiagnostics.
Panelists: Alison Fenney, Member, Board of Directors, Neurotechnology Industry Organization
Harry Tracy, President, NI Research
James Cavuoto, Editor & Publisher, Neurotech Reports
9:00 Investing in Neurotech Panel
A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information
technology? What are today’s deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?
Moderator: Joshua Pinto, Vice President, Healthcare Investment Banking, Credit Suisse
Panelists: Rahul Ballal, Entrepreneur-in-Residence, Versant Ventures
Laura Tadvalkar, Senior Associate, MP Healthcare Venture Management
Paulina Hill, Principal, Polaris Partners
Jamil Beg, Principal, 5AM Ventures
William Robb, Founding Partner, NovaQuest Capital Management
10:00 Coffee Break with Exhibit Viewing
10:40 Treatments for Alzheimer’s and Cognitive Disorders
As the population ages, the market for neurodegenerative disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies?
Can earlier or more accurate diagnosis improve outcomes?
Moderator: Michael Gold, Vice President, Development Neurosciences, AbbVie
Panelists: Christopher U. Missling, President and CEO, Anavex Life Sciences
Leen Kawas, President and CEO, M3 Biotechnology
Michael Mullan, CEO, Archer Pharmaceuticals
Casey Lynch, CEO, Cortexyme
Carlos Buesa, CEO, Oryzon
11:40 Developments on the Horizon for Pain and Epilepsy
Drugs and devices with novel mechanisms of action are on the horizon to decrease side effects and improve efficacy in treatment resistant populations for epilepsy and neuropathic pain. Hear from leading companies on their approaches.
Moderator: Robert H. Ring, Founder & President, Autós Consulting and Advisory Solutions
Panelists: Gregory T. Mayes, President, CEO & Founder, Engage Therapeutics, Inc.
Stephen Collins, CEO, Biscayne Neurotherapeutics
Ana Maiques, CEO, NeuroElectrics
Louis Mayaud, CSO, Mensia Technologies
12:40 pm Networking Luncheon
2:00 Internal and External Research and Development
Pharmaceutical and device companies are looking to provide complete solutions that span from prevention to treatment. Functions across the value chain will be kept in house or partnered. This panel of experts will discuss how they approach collaborations
with other companies, academic groups, research institutes, and platform companies.
Moderator: Christine de los Reyes, Vice President, Strategic Planning & Business Development, Alopexx Enterprises, LLC
Panelists: Jeff Erb, Senior Director, Strategy and Business Development, Medtronic
Isaac Veinbergs, Head, External Innovation, Sanofi
Eric Schaeffer, Senior Director, Neuroscience Innovation, Johnson & Johnson Innovation
3:00 Refreshment Break with Exhibit Viewing
3:45 Targeting Orphan Diseases
Orphan disorders are a hot area of investment due to perceived benefits with regulatory agencies, ready access to patients, and premium pricing. This session will gather companies developing treatments for ALS, lysosomal storage disorders, Huntington’s,
Moderator: Daniel Burch, Global Medical Officer, PPD Biotech
Panelists: Marc Martinell, CEO, Minoryx
Andrew Lim, CEO, Circumvent Pharmaceuticals
Lynn Durham, CEO & Founder, Stalicla
Michael Panzara, Franchise Lead, Neurology, WAVE Life Sciences Ltd.
Pushkal Garg, Chief Medical Officer, Alnylam Pharmaceuticals
David B. Clissold, Director, Hyman, Phelps & McNamara, P.C.
4:45 Strategic Development of Your Product Outside of the US:
The Australian Advantage
Tina Soulis, PhD, CEO, Neuroscience Trials Australia
This session will focus on case studies to demonstrate the approval process, regulatory framework, tax advantages, networks and overall capabilities that exist in Australia that could be used as part of a strategic development plan to save time, effort
and cost when planning your studies.
5:00 Emerging Company Showcase - Learn More About Our Participants
The third annual Emerging Company Showcase offers the stage to young neurotech companies to pitch their drug, device, diagnostic, or software to an audience of investors, CEOs, and executives in the field.
Moderator: Carla Lema Tome, Advisor, Neurotechnology Industry Organization
Participants: Lowry Curley, CEO, AxoSim, Inc
Dan Rizzuto, CEO, Nia Therapeutics
Shawn Ritchie, CEO and CSO, Med-Life Discoveries LP
Sefi Epel, CEO, Brainmarc
Visar Berisha, Co-Founder, CSO, Aural Analytics
Julie Collens, CEO, Vivid Genomics
Devon Greco, Founder and CEO, Narbis
Kumar Sripathirathan, CEO, DEHA
Steven Prawer, Director, Cofounder, CTO, iBIONICS
Eliav Shaked, Founder & CEO, RetiSpec
6:00 Welcome Reception with Exhibit Viewing
7:00 Close of Day
Wednesday, May 2, 2018
8:00 am Continental Breakfast
8:45 Keynote Presentation
Stephanie Fertig, MBA, Director, NINDS Small Business Programs, National Institute of Neurological Disorders and Stroke, National Institutes of Health
9:00 Partnering and Licensing in Neurotech Panel
Big pharma, biotech and medtech need to act to capitalize new innovations that provide solutions to the global demands in healthcare. This insider panel will discuss their areas of interest for in-licensing novel therapeutics, devices and diagnostics
and what they look for in a partner.
Moderator: John Reppas, Director, Public Policy, Neurotechnology Industry Organization
Panelists: Murali Gopalakrishnan, Head, Neuroscience Search and Evaluation, AbbVie
Robert Bagdorf, Vice President, Biopharmaceuticals Search and Evaluation, Pfizer
Matt Gunderman, Director, Business Development, Boston Scientific
10:00 Coffee Break with Exhibit Viewing
10:40 Parkinson’s and Other Movement Disorders
Current treatments for movement disorders can improve functioning, but suffer from side effects and “off” period, especially as the disease progresses. A number of novel pipeline pharmaceuticals and devices seek to address these issues. This
session will explore how disease modifying treatments alter the course of movement disorders, and how companion diagnostics can be leveraged to provide the most optimal outcomes for patients.
Moderator: Julie G Pilitsis, Chair Dept of Neuroscience & Experimental Therapeutics, Professor of Neurosurgery, Albany Medical College
Panelists: Ralph Kern, COO and CMO, BrainStorm Therapeutics
Randall W. Moreadith, CEO, Serina Therapeutics
Michael Almstetter, CEO, Origenis
Nader Yaghoubi, President and CEO, PathMaker Neurosystems Inc.
Jim DeMesa, CEO, Emerald Health Pharmaceuticals
11:40 Next-Generation Psychiatry
Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric illnesses represent a large portion of the neurotech market. Development of promising next-generation treatments is challenging. Novel devices and diagnostics are poised to change
the treatment landscape. This session will gather the most innovative treatments for mental health disorders.
Moderator: Manuel Lopez-Figueroa, Venture Partner, Bay City Capital
Panelists: Remy Luthringer, CEO, Minerva Neurosciences
Stephen Brannan, CMO, Karuna Pharmaceuticals
Atul Mahableshwarkar, Vice President, Clinical Development, BlackThorn Therapeutics
Michael J. Detke, CMO, Embera Therapeutics
Eric J. Messika, President and CEO, Coronis Neurosciences Ltd.
12:40 pm Networking Luncheon
2:00 Frontiers in Neurotechnology
In this session, we will hear from companies on the cutting edge. Novel neurostimulation devices are being developed for new markets. Closed loop systems create the promise of reduced side effects and more targeted treatment. New technology is yielding
benefits in delivery of therapeutics to brain. This session will preview next generation products and companies in neurotechnology.
Moderator: Daniel O’Connell, Founding member & Managing Partner, NeuroVentures; President and Chief Executive Officer, Acumen Pharmaceuticals, Inc.
Panelists: Abhishek Datta, CTO, Soterix
Susan Rosenbaum, Founder, Chairman and CEO, Lauren Sciences
Kate Rosenbluth, CEO, Cala Health
Craig A. Pierson, CEO, Centauri Surgical Systems
3:00 Challenges in Brain Trauma
Post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), stroke and other trauma have devastating consequences to the brain. This session will explore novel approaches for early detection and treatment of brain trauma to minimize sequela and
Moderator: Gary Wynn, MD, Associate Professor, Uniformed Services University
Panelists: Rick Doblin, Executive Director, MAPS
Dan Kincad, CEO, Sense Diagnostics
Michael Singer, CEO, Brainscope
4:00 Close of Conference